[Immunophenotypic and clinical features of Philadelphia chromosome positive adult lymphocytic leukemia].
OBJECTIVE
To sutdy the immunophenotypic and clinical features of Philadelphia chromosome positive adult acute lymphocytic leukemia (Ph+ ALL).


METHODS
Fifty-one previously untreated Ph+ ALL were included. Morphologic/cytochemistric, cytogenetic and immunophenotypic examinations were performed. Patients received daunorubicin-vincristine-prednisone (DOP) or DOP-asparaginas (DOLP) induction protocols. Two patients received autologous bone marrow transplantation (ABMT) as postremission therapy.


RESULTS
The 51 patients were among 158 patients with ALL (32.3%). Patients with Ph+ ALL were older and had a significantly higher incidence of peripheral leukocytosis and blasts, FAB L2 subtype, B lineage antigens expression and CD34 positivity. 42.1% of Ph+ ALL achieved complete remission (CR). Their remission duration was 4.5 months, the median time to CR was 54 days. Two patients receiving ABMT survived in remission 22 and 33 months, respectively.


CONCLUSIONS
Patients with Ph+ ALL are usually older, have FAB L2 morphology, and are B lineage antigens, CD34 positive. These patients had lower CR rate, shorter remission duration, and needed longer time to achieve CR.
First Affiliated Hospital, Suzhou Medical College, Jiangsu Institute of Hematology, Suzhou.
J
J
Li
Y
Y
Xue
C
C
Ruan
D000328:Adult; D000367:Age Factors; D018941:Antigens, CD19 / Q000096:biosynthesis; D018952:Antigens, CD34 / Q000096:biosynthesis; D018845:CD11 Antigens / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D008297:Male; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000276:immunology*; D012074:Remission Induction
D018941:Antigens, CD19; D018952:Antigens, CD34; D018845:CD11 Antigens